Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-analysis

Annals of Pharmacotherapy

Volumn 39, Issue 5, 2005, Pages 803-809

  Hemels, Michiel E H ^a,b   Einarson, Adrienne ^b   Koren, Gideon ^b   Lanctôt, Krista L ^c   Einarson, Thomas R ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressants; Depression; Spontaneous abortion

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ABORTION; ADULT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; DRUG USE; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC HETEROGENEITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 17644411089     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E547     Document Type: Review

References (52)

1. O'Hara MW. Social support, life events, and depression during pregnancy and the puerperium. Arch Gen Psychiatry 1986;43:569-73.
2. Kitamura T, Shima S, Sugawara M, Ioda MA. Psychological and social correlates of the onset of affective disorders among pregnant women. Psychosom Med 1993;23:967-75.
3. Marcus SM, Flynn H, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetric settings. J Women Health 2003;12:373-80.
4. Jarrahi-Zadeh A, Kane FJJ, Van de Castle RL, Lachenbruch PA, Ewing JA. Emotional and cognitive changes in pregnancy and early puerperium. Br J Psychiatry 1969;115:797-805.
5. Goldenberg RL, Gotlieb SJ. Social and psychological factors and pregnancy outcome. In: Complications of pregnancy: medical, surgical, gynaecologic, psychosocial and perinatal. Philadelphia: Williams and Wilkins, 1991:80-95.
6. Zax M, Sameroff AJ, Babigian HM. Birth outcomes in the offspring of mentally disordered women. Am J Orthopsychiatry 1977;47:218-9.
7. Zuckerman B, Amaro H, Bauchner H, Cabrai H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989;160:1107-11.
8. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome. Review of the literature and preliminary findings. Epidemiol Rev 1995;17:165-71.
9. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-9.
10. Zuckerman B, Bauchner H, Parker S. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990;11:190-4.
11. Thorngren-Jerneck K, Herbst A. Low 5-minute Apgar score: a population-based register study of 1 million term births. Obstet Gynecol 2001;98:1-7.
12. McGrath M, Sullivan M. Birth weight, neonatal morbidities, and school age outcomes in full-term and preterm infants. Issues Comprehens Pediatr Nurs 2002;25:231-54.
13. Allen MC. Preterm outcomes research: a critical component of neonatal intensive care. Ment Retard Dev D R 2003;8:221-33.
14. Glover V. Maternal stress or anxiety in pregnancy and emotional development of the child. Br J Psychiatry 1997;171:105-6.
15. Teixeira JM, Fisk NM, Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study. BMJ 1999;318:153-7.
16. Uno H, Lohmiller L, Thieme C. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. 1. Hippocampus. Brain Res Develop Brain Res 1990;53:157-67.
17. Uno H, Eisele S, Sakai A. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994;28:336-48.
18. Gotlib IH, Whiffen VE, Mount JH. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum. J Consult Clin Psychol 1989;57:269-74.
19. Klein MH, Essex MJ. Pregnant or depressed? The effect of overlap between symptoms of depression and somatic complaints of pregnancy on rates of major depression in the second trimester. Depression 1994;2:1994-5.
20. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
21. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnston Y, et al. A multicentre prospective controlled study to determine the safety of trazodone/nefazodone use during pregnancy. Can J Psychiatry 2003;48:106-10.
22. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
23. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multi-center study. JAMA 1998;279:609-10.
24. Garciá-Enguídanos A, Valero J, Luna S, Domínguez- Rojas V. Risk factors in miscarriage: a review. Eur J Obstet Gyn R B 2002;102:111-9.
25. Kesmodel U, Wisborg K, Olson FS, Henriksen TB, Secher NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. Alcohol Alcoholism 2002;37:87-92.
26. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989;26:541-5.
27. Cnattingius S, Signorello L, Anneren G, Clausson B, Ekborn A, Ljunger E, et al. Caffeine intake and the risk of first-trimester spontaneous abortions. N Engl J Med 2000;343:1839-45.
28. Anatomic Therapeutic Chemical classification of drugs. Oslo: World Health Organization Collaborating Center for Drug Utilization, 2004.
29. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
30. Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case control studies: "The number of patients needed to be treated for one additional patient to be harmed." BMJ 2000;320:503-6.
31. Egger M, Smith GD, Schneider M, Mindcer C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
32. Sterne JAC, Egger M, Davey G. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101-8.
33. Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:1046-55.
34. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
35. Sutton AJ, Song F, Gilbody SM, Abrams KR. Modelling publication bias in meta-analysis: a review. Stat Methods Med Res 2000;9:421-45.
36. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
37. Elwood JM. Critical appraisal of a cohort study. In: Causal relationships in medicine. 1st ed. Oxford: Oxford University Press, 1988:184-210.
38. Lichtenstein MJ, Mulrow CD, Elwood PC. Guidelines for reading case-control studies. J Chronic Dis 1987;40:893-903.
39. Feinstein AR. Observer variability. In: Clinical epidemiology. The architecture of clinical research. Philadelphia: WB Saunders, 1985:632-48.
40. Fleiss J. Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378-82.
41. Fleiss J, Nee J, Landis J. The large sample variance of kappa in the case of different sets of raters. Psychol Bull 1979;86:974-7.
42. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JGW, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
43. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-8.
44. Goldstein DJ, Sundell KL, Corbin LA. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1997;336:872-3.
45. Shakir S. Data. Southampton, UK: Drug Safety Research Unit, 1999.
46. Brunel P, Vial T, Roche I, Bertolotti E, Evreux JC. Follow-up of 151 pregnant women exposed to antidepressant treatment (MAOI excluded) during organogenesis. Therapie 1994;49:117-22.
47. Ericson A, Kallén B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999;55:503-8.
48. Emslie G, Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand Suppl 2000;403:26-34.
49. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995;15:417-20.
50. Webster J, Chandler J, Battistutta D. Pregnancy outcomes and health care use: effects of abuse. Am J Obstet Gynecol 1996;174:760-7.
51. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
52. McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10:285-94.